

PERRIGO[®]




**Perrigo Fiscal Fourth Quarter Conference Call
August 18, 2009**

Forward Looking Statements

Certain statements in this presentation are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created thereby. These statements relate to future events or the Company's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "potential" or other comparable terminology. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections. While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company's control. These and other important factors, including those discussed under "Risk Factors" in the Company's Form 10-K for the year ended June 27, 2009, as well as the Company's subsequent filings with the Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this presentation are made only as of the date hereof, and unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

All Category Update – Latest quarter



API Investment in India

The API business is a key strategic part of the Perrigo portfolio

Rationale:

- Improve API return on invested capital
- Vertical integration strategy
- Expanding position in low cost country

Value:

- Decrease future manufacturing and development costs
- Lower capital investment requirements
- Broaden product pipeline opportunities



GAAP Financials - From Continuing Operations

Perrigo Consolidated


(\$ in millions, except per share amounts)

| | Q4 2009 | Q4 2008 | % Change Y/Y |
|----------------------------------------|---------|---------|--------------|
| Net Sales | \$ 508 | \$ 474 | 7% |
| Cost of Sales | 344 | 339 | 2% |
| Gross Profit | 164 | 135 | 21% |
| Distribution and SG&A | 72 | 72 | -1% |
| R&D | 22 | 21 | 6% |
| Restructuring | 15 | 2 | |
| Operating Profit | 56 | 40 | 38% |
| Income from Continuing Ops | \$ 32 | \$ 32 | |
| Diluted EPS from Continuing Ops | \$ 0.35 | \$ 0.34 | 2% |


Margin Analysis

| Gross Margin | | |
|------------------|---------|------------|
| Q4 2009 | Q4 2008 | Change |
| 32.2% | 28.5% | ↑ +370 bps |
| Operating Margin | | |
| Q4 2009 | Q4 2008 | Change |
| 10.9% | 8.5% | ↑ +240 bps |

Gross Margin Q407-Q409



Operating Margin Q407-Q409



Non-GAAP Financials* — From Continuing Operations

| <i>(\$ in millions, except per share data)</i> | Q4 2009 | Q4 2008 | % Change Y/Y |
|-------------------------------------------------|-----------------|-----------------|-----------------|
| Net Sales | \$ 508.2 | \$ 474.3 | 7% |
| Reported Gross Profit | 163.9 | 135.1 | 21% |
| <i>Inventory step-up - Galpharm</i> | - | 2.9 | |
| <i>Impairment of intangible asset</i> | - | 10.3 | |
| Adjusted Gross Profit | \$ 163.9 | \$ 148.3 | 10% |
| Reported Operating Income | \$ 55.5 | \$ 40.4 | 38% |
| <i>Inventory step-up - Galpharm</i> | - | 2.9 | |
| <i>Impairment of intangible asset</i> | - | 10.3 | |
| <i>Restructuring costs - Germany</i> | 14.6 | - | |
| <i>Restructuring costs - West Coast</i> | - | 0.1 | |
| <i>Restructuring costs - United Kingdom</i> | - | 1.8 | |
| Adjusted Operating Income | \$ 70.2 | \$ 55.6 | 26% |
| Reported Income from Continuing Operations | \$ 32.3 | \$ 32.2 | 0% |
| <i>Inventory step-up - Galpharm</i> | - | 2.1 | |
| <i>Impairment of intangible asset</i> | - | 6.5 | |
| <i>Restructuring costs - Germany</i> | 14.6 | - | |
| <i>Restructuring costs - West Coast</i> | - | 0.1 | |
| <i>Restructuring costs - United Kingdom</i> | - | 1.3 | |
| Adjusted Income from Continuing Ops | \$ 46.9 | \$ 42.2 | 11% |
| Adjusted Diluted EPS from Continuing Ops | \$ 0.50 | \$ 0.44 | 13% |
| Diluted weighted average shares outstanding | 93.3 | 95.1 | |
| <i>Adjusted gross profit margin</i> | 32.2% | 31.3% | +90 bps |
| <i>Adjusted operating margin</i> | 13.8% | 11.7% | +210 bps |

*See attached financial schedule for full reconciliation to GAAP numbers


Adjusted Financials* - From Continuing Operations


Perrigo Consolidated

(\$ in millions, except per share amounts)

| | Q4 2009 | Q4 2008 | % Change Y/Y | Change as a % to sales |
|-------------------------------------------------|--------------|--------------|--------------|------------------------|
| Net Sales | \$ 508 | \$ 474 | 7% | |
| <i>Adjusted Cost of Sales</i> | 344 | 326 | 6% | |
| Adjusted Gross Profit | 164 | 148 | 10% | +90 bps |
| <i>Distribution and SG&A</i> | 72 | 72 | -1% | |
| <i>R&D</i> | 22 | 21 | 6% | |
| Adjusted Operating Profit | 70 | 56 | 26% | +210 bps |
| Adjusted Income from Continuing Ops | <u>\$ 47</u> | <u>\$ 42</u> | 11% | +30 bps |
| Adjusted Diluted EPS from Continuing Ops | \$ 0.50 | \$ 0.44 | 13% | |

Margin Analysis

| Adjusted Gross Margin | | |
|-----------------------|---------|---------------------------------------------------------------------------------------------|
| Q4 2009 | Q4 2008 | Change |
| 32.2% | 31.3% |  +90 bps |

| Adjusted Operating Margin | | |
|---------------------------|---------|----------------------------------------------------------------------------------------------|
| Q4 2009 | Q4 2008 | Change |
| 13.8% | 11.7% |  +210 bps |

Positive Impacts

- Improved volume and product mix in Rx and API 
- Pricing strategies to offset inflation
- SG&A cost management initiatives
- Positive foreign exchange impact on operating expenses 

Partial Negative Offsets

- Continued pressure from raw materials 
- Unfavorable foreign exchange impact on gross profit
- Increased R&D spend to invest in our future growth 

*See attached financial schedule for reconciliation to GAAP numbers

Adjusted Segment Financials*

-From Continuing Operations

Consumer Healthcare

(\$ in millions)

| | Q4 2009 | Q4 2008 | % Change Y/Y | Change as a % to sales |
|------------------------------------|---------|---------|--------------|------------------------|
| Net Sales | \$ 407 | \$ 375 | 9% | |
| Adjusted Cost of Sales | 287 | 261 | 10% | |
| Adjusted Gross Profit | 120 | 114 | 5% | -100 bps |
| Adjusted Operating Expenses | 64 | 57 | 12% | |
| Adjusted Operating Profit | \$ 56 | \$ 57 | -2% | -140 bps |

Margin Analysis

| Adjusted Gross Margin | | |
|---------------------------|---------|------------|
| Q4 2009 | Q4 2008 | Change |
| 29.4% | 30.4% | ↓ -100 bps |
| Adjusted Operating Margin | | |
| Q4 2009 | Q4 2008 | Change |
| 13.8% | 15.2% | ↓ -140 bps |

Margin Pressures

- Negative impact from foreign exchange
- Raw material inflation
- Increased R&D spend due to timing of certain products and clinical trials

Partial Positive Offsets

- Favorable product sales mix
- Margin contribution from U.S. acquisitions
- SG&A cost management initiatives

*See attached financial schedule for reconciliation to GAAP numbers

Adjusted Segment Financials*

-From Continuing Operations

Rx Pharmaceuticals

(\$ in millions)

| | Q4 2009 | Q4 2008 | % Change Y/Y | Change as a % to sales |
|----------------------------------|---------|---------|--------------|------------------------|
| Net Sales | \$ 49 | \$ 38 | 27% | |
| Adjusted Cost of Sales | 28 | 24 | 15% | |
| Adjusted Gross Profit | 21 | 14 | 47% | +570 bps |
| Operating Expenses | 9 | 10 | -8% | |
| Adjusted Operating Profit | \$ 12 | \$ 5 | 164% | +1290 bps |

Margin Analysis

| Adjusted Gross Margin | | |
|---------------------------|---------|-------------|
| Q4 2009 | Q4 2008 | Change |
| 43.0% | 37.3% | ↑ +570 bps |
| Adjusted Operating Margin | | |
| Q4 2009 | Q4 2008 | Change |
| 24.8% | 11.9% | ↑ +1290 bps |

Positive Impacts

- Increased sales of higher margin products
- Strong execution of pricing initiatives
- SG&A leverage on increased product sales
- R&D spend decrease YOY on lower legal costs



*See attached financial schedule for reconciliation to GAAP numbers

Adjusted Segment Financials*

-From Continuing Operations

API

(\$ in millions)

| | Q4 2009 | Q4 2008 | % Change Y/Y | Change as a % to sales |
|------------------------------------|-------------|-------------|-----------------|---------------------------|
| Net Sales | \$ 39 | \$ 38 | 2% | |
| Cost of Sales | 22 | 25 | -12% | |
| Gross Profit | 17 | 13 | 27% | +890 bps |
| Adjusted Operating Expenses | 8 | 10 | -19% | |
| Adjusted Operating Profit | <u>\$ 9</u> | <u>\$ 4</u> | 146% | +1390 bps |

Margin Analysis

| Gross Margin | | |
|---------------------------|---------|-------------|
| Q4 2009 | Q4 2008 | Change |
| 44.0% | 35.1% | ↑ +890 bps |
| Adjusted Operating Margin | | |
| Q4 2009 | Q4 2008 | Change |
| 23.7% | 9.8% | ↑ +1390 bps |

Positive Impacts

- Positive contribution from the sale of new products
- Improved plant efficiencies
- Execution of cost management initiatives
- Favorable changes in foreign exchange rates



*See attached financial schedule for reconciliation to GAAP numbers

Segment Financials -From Continuing Operations

Other

(\$ in millions)

| | Q4 2009 | Q4 2008 | % Change Y/Y | Change as a % to sales |
|---------------------------|---------|---------|-----------------|---------------------------|
| Net Sales | \$ 13 | \$ 23 | -41% | |
| Cost of Sales | 7 | 16 | -54% | |
| Gross Profit | 6 | 7 | -11% | +1520 bps |
| Operating Expenses | 4 | 6 | -39% | |
| Operating Profit | \$ 2 | \$ 1 | 191% | +1400 bps |

Margin Analysis

| Gross Margin | | |
|------------------|---------|-------------|
| Q4 2009 | Q4 2008 | Change |
| 44.3% | 29.1% | ↑ +1520 bps |
| Operating Margin | | |
| Q4 2009 | Q4 2008 | Change |
| 17.5% | 3.5% | ↑ +1400 bps |

Positive Impacts

- Change in customer contract whereby we are now a distributor to a customer



- Change in customer contract
- Improved operating efficiency
- Cost management



Partial Negative Offsets

- Lower sales volume in certain products




- Unfavorable changes in foreign currency exchange rates



Perrigo FY09 Final Performance vs. August Guidance*

-From Continuing Operations



*Ranges and results have been adjusted to exclude the Consumer Products business, except Cash Flow

Perrigo FY10 Outlook

-From Continuing Operations

| | |
|-----------------------------------------------|-------------------------------------------------|
| Consolidated Revenue Growth | 4% to 6% from Fiscal 2009 |
| Consolidated Operating Margin | 13% to 14% of Net Sales |
| Consumer Healthcare Revenue Growth | 6% to 8% from Fiscal 2009 |
| Cash Flow from Operations | \$220M to \$260M |
| Estimated Effective Worldwide Tax Rate | Approximately 28% (+/- 300 bps) |
| EPS from Continuing Operations | \$2.00 to \$2.12 (7% to 13% Y/Y Growth*) |

**Growth as compared to adjusted fiscal 2009 EPS from continuing operations*

Perrigo Fiscal 2010 Enablers

Goal 1: Execute on our Operating Plan

Goal 2: Execute API Strategic Transformation

Goal 3: Execute Nutrition Turnaround Strategy

Goal 4: International Expansion

**7% to 13%
Consolidated
EPS Growth***

Quality

Service


Innovation

Low Cost

People

*Growth as compared to adjusted fiscal 2009 EPS from continuing operations


Perrigo Store Brand Omeprazole Volume Share - FDMx



4 Weeks Ending

Launch Weeks

Store Brand Cetirizine 10MG Volume Share - FDMx



4 Weeks Ending

Appendix

Table II
PERRIGO COMPANY
RECONCILIATION OF NON-GAAP MEASURES
(in thousands, except per share amounts)
(unaudited)



| | Fourth Quarter | | | Fiscal Year | | |
|--------------------------------------------------------|-------------------|-------------------|----------|-------------------|-------------------|----------|
| | 2009 | 2008 | % Change | 2009 | 2008 | % Change |
| Net sales | \$ 508,209 | \$ 474,282 | 7% | \$ 2,006,862 | \$ 1,729,921 | 16% |
| Reported gross profit | \$ 163,853 | \$ 135,093 | 21% | \$ 595,997 | \$ 517,728 | 15% |
| Inventory step-up - Unico | - | - | | 1,062 | - | |
| Inventory step-up - Diba | - | - | | 1,503 | - | |
| Inventory step-up - JB Labs | - | - | | 358 | - | |
| Inventory step-up - Galpharm | - | 2,878 | | - | 5,756 | |
| Impairment of fixed assets | - | - | | 1,600 | - | |
| Impairment of intangible asset | - | 10,346 | | - | 10,346 | |
| Adjusted gross profit | <u>\$ 163,853</u> | <u>\$ 148,317</u> | 10% | <u>\$ 600,520</u> | <u>\$ 533,830</u> | 12% |
| Adjusted gross profit % | 32.2% | 31.3% | | 29.9% | 30.9% | |
| Reported operating expenses | \$ 108,329 | \$ 94,714 | 14% | \$ 348,690 | \$ 322,870 | 8% |
| Loss on asset exchange | - | - | | (639) | - | |
| Restructuring costs - Germany | (14,647) | - | | (14,647) | - | |
| Restructuring costs - West Coast | - | (143) | | - | (491) | |
| Restructuring costs - United Kingdom | - | (1,821) | | - | (1,821) | |
| Adjusted operating expenses | <u>\$ 93,682</u> | <u>\$ 92,750</u> | 1% | <u>\$ 333,404</u> | <u>\$ 320,558</u> | 4% |
| Adjusted operating expenses % | 18.4% | 19.6% | | 16.6% | 18.5% | |
| Reported operating income | \$ 55,524 | \$ 40,379 | 38% | \$ 247,307 | \$ 194,858 | 27% |
| Inventory step-up - Unico | - | - | | 1,062 | - | |
| Inventory step-up - Diba | - | - | | 1,503 | - | |
| Inventory step-up - JB Labs | - | - | | 358 | - | |
| Inventory step-up - Galpharm | - | 2,878 | | - | 5,756 | |
| Impairment of fixed assets | - | - | | 1,600 | - | |
| Impairment of intangible asset | - | 10,346 | | - | 10,346 | |
| Loss on asset exchange | - | - | | 639 | - | |
| Restructuring costs - Germany | 14,647 | - | | 14,647 | - | |
| Restructuring costs - West Coast | - | 143 | | - | 491 | |
| Restructuring costs - United Kingdom | - | 1,821 | | - | 1,821 | |
| Write-off of in-process R&D - Diba acquisition | - | - | | 279 | - | |
| Write-off of in-process R&D - Galpharm acquisition | - | - | | - | 2,786 | |
| Adjusted operating income | <u>\$ 70,171</u> | <u>\$ 55,567</u> | 26% | <u>\$ 267,395</u> | <u>\$ 216,058</u> | 24% |
| Adjusted operating income % | 13.8% | 11.7% | | 13.3% | 12.5% | |
| Reported income from continuing operations | \$ 32,280 | \$ 32,160 | 0% | \$ 141,098 | \$ 140,197 | 1% |
| Inventory step-up - Unico (5) | - | - | | 645 | - | |
| Inventory step-up - Diba (1) | - | - | | 1,082 | - | |
| Inventory step-up - JB Labs (2) | - | - | | 229 | - | |
| Inventory step-up - Galpharm (1) | - | 2,072 | | - | 4,144 | |
| Impairment of fixed assets (4) | - | - | | 992 | - | |
| Impairment of intangible asset (3) | - | 6,518 | | - | 6,518 | |
| Investment impairment (6) | - | - | | 15,104 | - | |
| Loss on asset exchange (6) | - | - | | 639 | - | |
| Restructuring costs - Germany (6) | 14,647 | - | | 14,647 | - | |
| Restructuring costs - West Coast (3) | - | 90 | | - | 309 | |
| Restructuring costs - United Kingdom (1) | - | 1,311 | | - | 1,311 | |
| Write-off of in-process R&D - Diba acquisition (1) | - | - | | 201 | - | |
| Write-off of in-process R&D - Galpharm acquisition (1) | - | - | | - | 2,006 | |
| Adjusted income from continuing operations | <u>\$ 46,927</u> | <u>\$ 42,151</u> | 11% | <u>\$ 174,637</u> | <u>\$ 154,485</u> | 13% |
| Diluted earnings per share from continuing operations | | | | | | |
| Reported | \$ 0.35 | \$ 0.34 | 2% | \$ 1.51 | \$ 1.47 | 2% |
| Adjusted | \$ 0.50 | \$ 0.44 | 13% | \$ 1.87 | \$ 1.62 | 15% |
| Diluted weighted average shares outstanding | 93,290 | 95,076 | | 93,629 | 95,210 | |

- (1) Net of taxes at 28%
- (2) Net of taxes at 36%
- (3) Net of taxes at 37%
- (4) Net of taxes at 38%
- (5) Net of taxes at 39.3%
- (6) No tax impact

*All information based on continuing operations.

Table II (Continued)
REPORTABLE SEGMENTS
RECONCILIATION OF NON-GAAP MEASURES
(in thousands)
(unaudited)

| | Fourth Quarter | | | Fiscal Year | | |
|--------------------------------------|-------------------|-------------------|----------|-------------------|-------------------|----------|
| | 2009 | 2008 | % Change | 2009 | 2008 | % Change |
| Consumer Healthcare | | | | | | |
| Net sales | \$ 407,009 | \$ 374,645 | 9% | \$ 1,638,770 | \$ 1,336,140 | 23% |
| Reported gross profit | \$ 119,782 | \$ 111,037 | 8% | \$ 460,133 | \$ 377,765 | 22% |
| Inventory step-up - Unico | - | - | | 1,062 | - | |
| Inventory step-up - Diba | - | - | | 1,503 | - | |
| Inventory step-up - JB Labs | - | - | | 358 | - | |
| Inventory step-up - Galpharm | - | 2,878 | | - | 5,756 | |
| Impairment of fixed assets | - | - | | 1,600 | - | |
| Adjusted gross profit | <u>\$ 119,782</u> | <u>\$ 113,915</u> | 5% | <u>\$ 464,656</u> | <u>\$ 383,521</u> | 21% |
| Adjusted gross profit % | 29.4% | 30.4% | | 28.4% | 28.7% | |
| Reported operating expenses | \$ 63,725 | \$ 58,932 | 8% | \$ 226,379 | \$ 205,111 | 10% |
| Loss on asset exchange | - | - | | (639) | - | |
| Restructuring costs - West Coast | - | (143) | | - | (491) | |
| Restructuring costs - United Kingdom | - | (1,821) | | - | (1,821) | |
| Adjusted operating expenses | <u>\$ 63,725</u> | <u>\$ 56,968</u> | 12% | <u>\$ 225,740</u> | <u>\$ 202,799</u> | 11% |
| Adjusted operating expenses % | 15.7% | 15.2% | | 13.8% | 15.2% | |
| Reported operating income | \$ 56,059 | \$ 52,105 | 8% | \$ 233,756 | \$ 172,654 | 35% |
| Inventory step-up - Unico | - | - | | 1,062 | - | |
| Inventory step-up - Diba | - | - | | 1,503 | - | |
| Inventory step-up - JB Labs | - | - | | 358 | - | |
| Inventory step-up - Galpharm | - | 2,878 | | - | 5,756 | |
| Impairment of fixed assets | - | - | | 1,600 | - | |
| Loss on asset exchange | - | - | | 639 | - | |
| Restructuring costs - West Coast | - | 143 | | - | 491 | |
| Restructuring costs - United Kingdom | - | 1,821 | | - | 1,821 | |
| Adjusted operating income | <u>\$ 56,059</u> | <u>\$ 56,947</u> | -2% | <u>\$ 238,918</u> | <u>\$ 180,722</u> | 32% |
| Adjusted operating income % | 13.8% | 15.2% | | 14.6% | 13.5% | |

Table II (Continued)
REPORTABLE SEGMENTS
RECONCILIATION OF NON-GAAP MEASURES
(in thousands)
(unaudited)



| | Fourth Quarter | | | Fiscal Year | | |
|----------------------------------------------------|----------------|-------------|----------|-------------|-------------|----------|
| | 2009 | 2008 | % Change | 2009 | 2008 | % Change |
| Rx Pharmaceuticals | | | | | | |
| Net sales | \$ 48,840 | \$ 38,425 | 27% | \$ 164,163 | \$ 161,271 | 2% |
| Reported gross profit | \$ 21,010 | \$ 3,969 | | \$ 63,801 | \$ 58,622 | 9% |
| Impairment of intangible asset | - | 10,346 | | - | 10,346 | |
| Adjusted gross profit | \$ 21,010 | \$ 14,315 | 47% | \$ 63,801 | \$ 68,968 | -7% |
| Adjusted gross profit % | 43.0% | 37.3% | | 38.9% | 42.8% | |
| Reported operating income (loss) | \$ 12,090 | \$ (5,774) | -309% | \$ 29,028 | \$ 21,386 | 36% |
| Impairment of intangible asset | - | 10,346 | | - | 10,346 | |
| Adjusted operating income | \$ 12,090 | \$ 4,572 | 164% | \$ 29,028 | \$ 31,732 | -9% |
| Adjusted operating income % | 24.8% | 11.9% | | 17.7% | 19.7% | |
| API | | | | | | |
| Net sales | \$ 38,940 | \$ 38,313 | 2% | \$ 136,002 | \$ 149,553 | -9% |
| Reported operating expenses | \$ 22,529 | \$ 9,678 | | \$ 47,124 | \$ 34,717 | 36% |
| Restructuring costs - Germany | (14,647) | - | | (14,647) | - | |
| Adjusted operating expenses | \$ 7,882 | \$ 9,678 | -19% | \$ 32,477 | \$ 34,717 | -6% |
| Adjusted operating expenses % | 20.2% | 25.3% | | 23.9% | 23.2% | |
| Reported operating income (loss) | \$ (5,409) | \$ 3,752 | -244% | \$ 433 | \$ 20,475 | -98% |
| Restructuring costs - Germany | 14,647 | - | | 14,647 | - | |
| Adjusted operating income | \$ 9,238 | \$ 3,752 | 146% | \$ 15,080 | \$ 20,475 | -26% |
| Adjusted operating income % | 23.7% | 9.8% | | 11.1% | 13.7% | |
| Unallocated | | | | | | |
| Reported operating loss | \$ (9,569) | \$ (10,513) | -9% | \$ (23,590) | \$ (26,687) | -12% |
| Write-off of in-process R&D - Diba acquisition | - | - | | 279 | - | |
| Write-off of in-process R&D - Galpharm acquisition | - | - | | - | 2,786 | |
| Adjusted operating loss | \$ (9,569) | \$ (10,513) | -9% | \$ (23,311) | \$ (23,901) | -2% |

*All information based on continuing operations.

Table III
PERRIGO COMPANY
RECONCILIATION OF NON-GAAP MEASURES
(in thousands)
(unaudited)

| | Fourth Quarter Reported Cost of Sales | | Adjustment - Inventory Step-Up | | Adjustment - Intangible Asset Impairment | | Fourth Quarter Adjusted Cost of Sales | |
|---------------------|------------------------------------------|------------------|-----------------------------------|------------------|---------------------------------------------|-------------------|------------------------------------------|------------------|
| | 2009 | 2008 | 2009 | 2008 | 2009 | 2008 | 2009 | 2008 |
| Segments | | | | | | | | |
| Consumer Healthcare | \$287,226 | \$263,607 | \$ - | \$(2,878) | \$ - | \$ - | \$287,226 | \$260,729 |
| Rx Pharmaceuticals | 27,829 | 34,456 | - | - | - | (10,346) | 27,829 | 24,110 |
| API | 21,820 | 24,884 | - | - | - | - | 21,820 | 24,884 |
| Other | 7,481 | 16,242 | - | - | - | - | 7,481 | 16,242 |
| Total | <u>\$344,356</u> | <u>\$339,189</u> | <u>\$ -</u> | <u>\$(2,878)</u> | <u>\$ -</u> | <u>\$(10,346)</u> | <u>\$344,356</u> | <u>\$325,965</u> |

*All information based on continuing operations.